Key Highlights

  • Healius became the exclusive Australian distributor for the Promarker blood-test portfolio.
  • The initial three-year agreement includes a mutual option for another three years.
  • Commercial terms are confidential and revenue cannot yet be reliably estimated.
  • A phased Australian rollout is expected during FY27 without public reimbursement at launch.

Proteomics International Laboratories Limited (ASX:PIQ) drew market attention after appointing Healius Limited (ASX:HLS) as exclusive Australian distributor for its Promarker blood tests. The three-year agreement, announced on 22 July 2026, provides access to a national pathology network and includes an option for a further three years.

PIQ shares traded as high as AUD 0.225 on the announcement date, a gain of roughly 50% before easing. The response reflected the commercial reach of the agreement, although no revenue forecast has been provided and the phased rollout is not expected until FY27.

How is the Healius agreement structured?

Healius will manage specimen collection, pathology distribution and engagement with referring doctors. Proteomics International retains laboratory testing, clinical reporting, quality responsibilities and regulatory compliance. No intellectual property changes hands.

Commercial terms remain confidential. Proteomics International said potential revenue cannot be reliably estimated because the portfolio is at an early stage of commercialisation. The agreement therefore establishes a distribution pathway rather than a confirmed revenue outcome.

What does Healius bring to the rollout?

Proteomics International cited access to more than 2,000 patient collection centres and Healius relationships with general practitioners, specialists and hospitals. Using an established network allows the smaller diagnostics developer to avoid building a national collection footprint independently.

The national footprint may also support a more consistent specimen pathway as individual tests move through the planned phased commercial launch.

The arrangement follows the partnership model outlined in Proteomics International’s April 2026 strategic plan. That plan favoured distributors in Australia and the United States and targeted an Australian appointment during the first half of FY27.

The Promarker portfolio targets several conditions

Promarker tests measure combinations of proteins in blood plasma to estimate disease risk. PromarkerD is designed to predict diabetic kidney disease before conventional markers show damage. PromarkerEso targets oesophageal adenocarcinoma, while PromarkerEndo addresses endometriosis. OxiDx measures oxidative stress.

The company has reported negative predictive values of 95%–97% for PromarkerD and 99.9% for PromarkerEso, together with 83% sensitivity for PromarkerEndo. These are company-reported clinical validation results rather than regulatory determinations. Patent coverage has also expanded for PromarkerEndo and PromarkerEso.

Regulation and reimbursement remain central

In the United States, a reimbursement price of USD 390.75 per test was set for the next-generation PromarkerD from 1 January 2026, although broader coverage is still being pursued. Testing is conducted through the company’s certified California reference laboratory.

Australia remains at an earlier stage. PromarkerD was previously declined for inclusion on the Australian Register of Therapeutic Goods because of insufficient data on the manufactured version. Initial commercialisation is expected to use a private-pay model, with Medicare Benefits Schedule reimbursement a later objective.

What Investors May Watch Next

  • The FY27 launch sequence for individual Promarker tests.
  • Private-pay testing volumes through the Healius network.
  • Australian regulatory and reimbursement progress.
  • Quarterly cash receipts, operating losses and funding requirements.

Risks

The agreement does not provide a reliable revenue estimate, and commercial adoption may be slower than expected. Regulatory approvals, reimbursement, test performance, clinician adoption, laboratory execution, competition, operating losses and future funding may affect progress. Share-price movements may remain volatile.